N,N-dicarbamimidoylmorpholine-4-carboximidamide;hydrochloride

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: N,N-dicarbamimidoylmorpholine-4-carboximidamide;hydrochloride
• 化学式: C7H16ClN7O
• 分子量: 249.7
• InChiKey: NCYGNXXMVNGYHD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.24
• 重原子数：
  16
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  139
• 氢给体数：
  6
• 氢受体数：
  4

文献信息

• [EN] TREATMENT OF LYMPHANGIOLEIOMYOMATOSIS<br/>[FR] TRAITEMENT DE LA LYMPHANGIOLÉIOMYOMATOSE
  申请人：BRIGHAM & WOMENS HOSPITAL

  公开号：WO2014137978A1

  公开（公告）日：2014-09-12

  Embodiments disclosed herein provide compositions and methods for treating lymphangioleiomyomatosis (LAM) comprising inhibiting COX overexpression and prostaglandin over production by administering at least one COX inhibitor and/or prostaglandin biosynthetic pathway inhibitors. Lymphangioleiomyomatosis (LAM) is a rare lung disease. Some LAM occurances are associated with mutations in the tuberous sclerosis complex (TSC) locus. LAM occurs almost exclusively in women, usually of childbearing age.
• [EN] TREATMENT OF MTOR HYPERACTIVE RELATED DISEASES AND DISORDERS<br/>[FR] TRAITEMENT DE MALADIES ET DE TROUBLES ASSOCIÉS À UNE HYPERACTIVITÉ DE MTOR
  申请人：BRIGHAM & WOMENS HOSPITAL

  公开号：WO2014201111A1

  公开（公告）日：2014-12-18

  Embodiments disclosed herein provide compositions and methods for treating cancer having deregulated mTOR signaling or mTOR hyperactivity, e.g., lymphangioleiomyomatosis (LAM), LAM/TSC or treating and/or management of tuberous sclerosis complex (TSC). Such methods and compositions comprise at least one compound selected from the group consisting of nateglinide, Z-L-Phe chloromethyl ketone, clemastine fumarate, supercinnamaldehyde, practolol, fluvastatin Na, sulindac, BIO, amorolfine, spectinomucin, sibutramine HCl, nelfinavir mesylate, moroxydine HCl, nicotine ditartrate, trequinsin, meglumine, tizanidine HCl, CGP-74514A hydrochloride, tioconazole, TOVOK™ (afatinib), or kasugamycin.